Evonile Pharma Limited, formerly Novartis India, has received board approval to raise up to Rs 900 crore via a rights issue of partly paid-up equity shares. A dedicated committee has been formed to finalize the pricing, entitlement ratio, and record date. The move signals a major capital expansion effort, pending further regulatory and shareholder approvals.
Evonile Pharma Board Approves Rs 900 Crore Rights Issue
Aggregate issue size is capped at Rs 900 crore with a face value of Rs 5 per share.
Rights Issue Committee formed to finalize pricing, entitlement ratio, and record date.
Reader Takeaway: Company moves to bolster capital reserves; wait for committee’s decision on pricing and entitlement ratios.
What just happened
Evonile Pharma Limited, previously known as Novartis India Limited, has formally approved a fundraising plan through a rights issue. The board of directors authorized the issuance of partly paid-up equity shares with a face value of Rs 5 each, aiming to raise an aggregate amount not exceeding Rs 900 crore.
Why this matters
This capital infusion is a significant step for the company's growth strategy. By issuing partly paid-up shares, the company allows investors to pay the total amount in installments, which can be an efficient way to manage cash flow. The constitution of a Rights Issue Committee is a critical governance move, granting specific powers to finalize the mechanics of the issuance, including the record date and issue price.
What changes now
Shareholders will be consulted through a postal ballot process to gain the necessary approvals for this fundraising exercise. Management has also launched a new corporate website, www.evonilepharma.com, as part of its rebranding and outreach efforts. Investors should watch for the subsequent notification of the record date, which will determine eligibility for the rights entitlement.
Governance structure
The Rights Issue Committee, tasked with overseeing the execution of the issue, includes Managing Director and CEO Mr. Vikas Gupta, Non-Executive Director Dr. Jagriti Gupta, and Independent Director Mr. Shashank Sinha. This committee holds the authority to appoint necessary intermediaries and decide the final timing of the issue.
What to track next
Key items to monitor include the upcoming filing regarding the entitlement ratio and the specific issue price per share. Further updates on the progress of the postal ballot will also be critical for investors planning their participation.